首页 > 最新文献

Journal of Breast Imaging最新文献

英文 中文
The FDA Enhancing Quality Using the Inspection Program (EQUIP) Breast Imaging Quality Initiative. 5-Year Clinical Experience. 美国食品药物管理局利用检查计划提高质量(EQUIP)乳腺成像质量计划。5 年临床经验。
IF 2 Q3 ONCOLOGY Pub Date : 2024-07-30 DOI: 10.1093/jbi/wbae034
Jeffrey R Hawley, Cynthia Ha, Linda Cai, Clayton R Taylor

Objectives: To evaluate the effects of the Enhancing Quality Using the Inspection Program (EQUIP) on quality control (QC) and quality assurance (QA) at an academic medical center.

Methods: EQUIP audit logs for technologist image quality review as well as mammography unit QA and QC formed the basis for study data. One randomly selected screening mammogram was evaluated by the lead interpreting physician (LIP) using EQUIP criteria for each technologist for each imaging site worked, initially semiannually and then monthly. One randomly selected screening mammogram interpreted by each interpreting physician (IP) for each imaging site was evaluated on a semiannual basis. Quarterly, the LIP reviewed QA and QC logs for each mammography unit with deficiencies further investigated.

Results: Of 214 965 eligible screening mammograms performed, 5955 (2.8%) underwent EQUIP image quality review. Five were found to be technically inadequate (0.08%, 5955/214 965). The LIP identified 20 significant interpretive differences compared with the clinical interpretation resulting in 10 biopsies and 7 previously undetected malignancies, with supplemental cancer detection rate of 1.2/1000 cases reviewed. Two hundred ninety mammography unit QA/QC reviews identified 31 potential deficiencies, 29 of which were due to human documentation error (93.4%).

Conclusion: EQUIP review of both IP and technologists' quality and mammography unit QA/QC logs as performed identified few deficiencies. EQUIP policies should be evaluated at each institution and modified to best utilize resources and provide opportunities for meaningful quality improvement. Although not an EQUIP focus, supplemental cancer detection was observed as might be expected with double reading.

目的评估学术医疗中心的 "利用检查项目提高质量"(EQUIP)对质量控制(QC)和质量保证(QA)的影响:方法: EQUIP 对技师图像质量审查以及乳腺 X 射线照相单位质量保证和质量控制的审核记录构成了研究数据的基础。由首席判读医师(LIP)根据 EQUIP 标准对每个影像中心的每位技师随机抽取一张筛查乳房 X 光照片进行评估,最初每半年评估一次,后来每月评估一次。每半年对每个造影点的每位口译医生(IP)口译的随机抽取的乳房 X 光筛查照片进行一次评估。每季度,LIP 审查每个乳腺造影单位的质量保证和质量控制日志,并进一步调查不足之处:在 214 965 例合格的乳腺 X 光筛查中,有 5955 例(2.8%)接受了 EQUIP 图像质量审查。其中 5 例(2.8%)被认定为技术缺陷(0.08%,5955/214965)。LIP 发现了 20 个与临床解释有重大差异的解释,导致 10 例活检和 7 例以前未发现的恶性肿瘤,补充癌症检出率为 1.2/1000。290 个乳腺放射摄影单位的质量保证/质量控制审查发现了 31 项潜在缺陷,其中 29 项是人为文件错误造成的(93.4%):结论:EQUIP 对 IP 和技师的质量以及乳腺 X 射线照相单位的 QA/QC 日志进行审查,发现的缺陷很少。各机构应对 EQUIP 政策进行评估和修改,以充分利用资源,提供有意义的质量改进机会。虽然不是 EQUIP 的重点,但也观察到了双读时可能出现的癌症检测补充。
{"title":"The FDA Enhancing Quality Using the Inspection Program (EQUIP) Breast Imaging Quality Initiative. 5-Year Clinical Experience.","authors":"Jeffrey R Hawley, Cynthia Ha, Linda Cai, Clayton R Taylor","doi":"10.1093/jbi/wbae034","DOIUrl":"10.1093/jbi/wbae034","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effects of the Enhancing Quality Using the Inspection Program (EQUIP) on quality control (QC) and quality assurance (QA) at an academic medical center.</p><p><strong>Methods: </strong>EQUIP audit logs for technologist image quality review as well as mammography unit QA and QC formed the basis for study data. One randomly selected screening mammogram was evaluated by the lead interpreting physician (LIP) using EQUIP criteria for each technologist for each imaging site worked, initially semiannually and then monthly. One randomly selected screening mammogram interpreted by each interpreting physician (IP) for each imaging site was evaluated on a semiannual basis. Quarterly, the LIP reviewed QA and QC logs for each mammography unit with deficiencies further investigated.</p><p><strong>Results: </strong>Of 214 965 eligible screening mammograms performed, 5955 (2.8%) underwent EQUIP image quality review. Five were found to be technically inadequate (0.08%, 5955/214 965). The LIP identified 20 significant interpretive differences compared with the clinical interpretation resulting in 10 biopsies and 7 previously undetected malignancies, with supplemental cancer detection rate of 1.2/1000 cases reviewed. Two hundred ninety mammography unit QA/QC reviews identified 31 potential deficiencies, 29 of which were due to human documentation error (93.4%).</p><p><strong>Conclusion: </strong>EQUIP review of both IP and technologists' quality and mammography unit QA/QC logs as performed identified few deficiencies. EQUIP policies should be evaluated at each institution and modified to best utilize resources and provide opportunities for meaningful quality improvement. Although not an EQUIP focus, supplemental cancer detection was observed as might be expected with double reading.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2023-2024 Editor's Recognition Awards. 2023-2024 年编辑表彰奖。
IF 2 Q3 ONCOLOGY Pub Date : 2024-07-30 DOI: 10.1093/jbi/wbae032
Jay A Baker
{"title":"2023-2024 Editor's Recognition Awards.","authors":"Jay A Baker","doi":"10.1093/jbi/wbae032","DOIUrl":"https://doi.org/10.1093/jbi/wbae032","url":null,"abstract":"","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unknown Case: Metastatic Breast Cancer With Abnormal Soft Tissue Mass in the Shoulder. 未知病例:转移性乳腺癌伴肩部异常软组织肿块
IF 1.5 Q3 Medicine Pub Date : 2024-06-13 DOI: 10.1093/jbi/wbae005
Colin Marshall, Holly Marshall
{"title":"Unknown Case: Metastatic Breast Cancer With Abnormal Soft Tissue Mass in the Shoulder.","authors":"Colin Marshall, Holly Marshall","doi":"10.1093/jbi/wbae005","DOIUrl":"https://doi.org/10.1093/jbi/wbae005","url":null,"abstract":"","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unknown Case: Man With a Palpable Retroareolar Mass. 不明病例:可触及乳晕后肿块的男子。
IF 1.5 Q3 Medicine Pub Date : 2024-06-04 DOI: 10.1093/jbi/wbae003
Hieu Diep, Cherie M Kuzmiak
{"title":"Unknown Case: Man With a Palpable Retroareolar Mass.","authors":"Hieu Diep, Cherie M Kuzmiak","doi":"10.1093/jbi/wbae003","DOIUrl":"https://doi.org/10.1093/jbi/wbae003","url":null,"abstract":"","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141248770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalent vs Incident Screen: Why Does It Matter? 普遍筛查与事件筛查:为什么这很重要?
IF 1.5 Q3 Medicine Pub Date : 2024-05-27 DOI: 10.1093/jbi/wbad096
Jessica H Hayward, Amie Y Lee, Edward A Sickles, Kimberly M Ray

There are important differences in the performance and outcomes of breast cancer screening in the prevalent compared to the incident screening rounds. The prevalent screen is the first screening examination using a particular imaging technique and identifies pre-existing, undiagnosed cancers in the population. The incident screen is any subsequent screening examination using that technique. It is expected to identify fewer cancers than the prevalent screen because it captures only those cancers that have become detectable since the prior screening examination. The higher cancer detection rate at prevalent relative to incident screening should be taken into account when analyzing the medical audit and effectiveness of new screening technologies.

在乳腺癌筛查中,普遍筛查与偶发筛查的效果和结果存在重大差异。流行筛查是使用特定成像技术进行的首次筛查,可识别人群中预先存在的未确诊癌症。偶发筛查是指使用该技术进行的任何后续筛查。与流行筛查相比,事件筛查发现的癌症数量较少,因为事件筛查只发现那些在上次筛查后才可检测到的癌症。在分析新筛查技术的医疗审计和有效性时,应考虑到普遍筛查的癌症检出率高于偶然筛查。
{"title":"Prevalent vs Incident Screen: Why Does It Matter?","authors":"Jessica H Hayward, Amie Y Lee, Edward A Sickles, Kimberly M Ray","doi":"10.1093/jbi/wbad096","DOIUrl":"10.1093/jbi/wbad096","url":null,"abstract":"<p><p>There are important differences in the performance and outcomes of breast cancer screening in the prevalent compared to the incident screening rounds. The prevalent screen is the first screening examination using a particular imaging technique and identifies pre-existing, undiagnosed cancers in the population. The incident screen is any subsequent screening examination using that technique. It is expected to identify fewer cancers than the prevalent screen because it captures only those cancers that have become detectable since the prior screening examination. The higher cancer detection rate at prevalent relative to incident screening should be taken into account when analyzing the medical audit and effectiveness of new screening technologies.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast Hemangiomas: Imaging Features With Histopathology Correlation. 乳腺血管瘤:影像学特征与组织病理学相关性。
IF 1.5 Q3 Medicine Pub Date : 2024-05-27 DOI: 10.1093/jbi/wbae011
Alysha Dhami, Meng Hao, Uzma Waheed, Brittany Z Dashevsky, Gregory R Bean

Breast hemangiomas are rare benign vascular lesions. In a previously performed review of approximately 10,000 breast surgical pathology results, roughly 0.15% (15/~10 000) were hemangiomas. Hemangiomas are more frequent in women and have a documented age distribution of 1.5 to 82 years. They are most often subcutaneous or subdermal and anterior to the anterior mammary fascia but may rarely be seen in the pectoralis muscles or chest wall. On imaging, breast hemangiomas typically present as oval or round masses, often measuring less than 2.5 cm, with circumscribed or mostly circumscribed, focally microlobulated margins, equal or high density on mammography, and variable echogenicity on US. Calcifications, including phleboliths, can be seen. Color Doppler US often shows hypovascularity or avascularity. MRI appearance can vary, although hemangiomas are generally T2 hyperintense and T1 hypointense with variable enhancement. Pathologic findings vary by subtype, which include perilobular, capillary, cavernous, and venous hemangiomas. If core biopsy pathology results are benign, without atypia, and concordant with imaging and clinical findings, surgical excision is not routinely indicated. Because of histopathologic overlap with well-differentiated or low-grade angiosarcomas, surgical excision may be necessary for definitive diagnosis. Findings that are more common with angiosarcomas include size greater than 2 cm, hypervascularity on Doppler US, irregular shape, and invasive growth pattern.

乳腺血管瘤是一种罕见的良性血管病变。以前曾对大约 10,000 例乳腺手术病理结果进行过审查,其中大约 0.15%(15/~10,000 例)为血管瘤。血管瘤多见于女性,年龄分布在 1.5 岁至 82 岁之间。它们最常见于皮下或皮下,位于乳腺前筋膜的前方,但很少见于胸肌或胸壁。在影像学上,乳腺血管瘤通常表现为椭圆形或圆形肿块,大小通常小于 2.5 厘米,边缘呈环形或多环形,病灶边缘呈微细球状,在乳腺 X 光检查中呈等密度或高密度,在 US 检查中呈不同的回声。可见钙化,包括静脉结石。彩色多普勒超声常常显示血管过少或无血管。核磁共振成像的表现各不相同,但血管瘤一般为 T2 高强化和 T1 低强化,并伴有不同程度的增强。病理结果因亚型而异,包括周围型、毛细血管瘤、海绵状血管瘤和静脉血管瘤。如果核心活检病理结果为良性,无不典型性,且与影像学和临床结果一致,则不需要常规进行手术切除。由于组织病理学结果与分化良好或低级别血管肉瘤重叠,可能需要进行手术切除以明确诊断。血管肉瘤更常见的症状包括:大小超过 2 厘米、多普勒超声显示血管过多、形状不规则以及侵袭性生长模式。
{"title":"Breast Hemangiomas: Imaging Features With Histopathology Correlation.","authors":"Alysha Dhami, Meng Hao, Uzma Waheed, Brittany Z Dashevsky, Gregory R Bean","doi":"10.1093/jbi/wbae011","DOIUrl":"10.1093/jbi/wbae011","url":null,"abstract":"<p><p>Breast hemangiomas are rare benign vascular lesions. In a previously performed review of approximately 10,000 breast surgical pathology results, roughly 0.15% (15/~10 000) were hemangiomas. Hemangiomas are more frequent in women and have a documented age distribution of 1.5 to 82 years. They are most often subcutaneous or subdermal and anterior to the anterior mammary fascia but may rarely be seen in the pectoralis muscles or chest wall. On imaging, breast hemangiomas typically present as oval or round masses, often measuring less than 2.5 cm, with circumscribed or mostly circumscribed, focally microlobulated margins, equal or high density on mammography, and variable echogenicity on US. Calcifications, including phleboliths, can be seen. Color Doppler US often shows hypovascularity or avascularity. MRI appearance can vary, although hemangiomas are generally T2 hyperintense and T1 hypointense with variable enhancement. Pathologic findings vary by subtype, which include perilobular, capillary, cavernous, and venous hemangiomas. If core biopsy pathology results are benign, without atypia, and concordant with imaging and clinical findings, surgical excision is not routinely indicated. Because of histopathologic overlap with well-differentiated or low-grade angiosarcomas, surgical excision may be necessary for definitive diagnosis. Findings that are more common with angiosarcomas include size greater than 2 cm, hypervascularity on Doppler US, irregular shape, and invasive growth pattern.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypia Involving Fibroadenomas: Outcomes and Upgrade Rates. 涉及纤维腺瘤的不典型性:结果和升级率
IF 1.5 Q3 Medicine Pub Date : 2024-05-27 DOI: 10.1093/jbi/wbae013
Allison Aripoli, Onalisa Winblad, Christa Balanoff, Jessica Peterson, Camron Smith, Ashley Huppe, Molly Hill, Daniela Wermuth, Nika Gloyeske

Objective: Fibroadenomas (FAs) involved by atypia are rare. Consensus guidelines for management of FAs involved by atypia when diagnosed on image-guided biopsy do not exist because of limited data reporting surgical upgrade rates to ductal carcinoma in situ (DCIS) or invasive malignancy. Therefore, these lesions commonly undergo surgical excision.

Methods: This single-institution retrospective study identified cases of FAs involved by atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and/or lobular carcinoma in situ (LCIS) diagnosed on image-guided biopsy between January 2014 and April 2023 to determine upgrade rates. Cases with incidental atypia adjacent to but not involving FAs were excluded.

Results: Among 1736 FAs diagnosed on image-guided biopsy, 32 cases (1.8%) were FAs involved by atypia including 43.8% (14/32) ALH, 28.1% (9/32) ADH, 18.8% (6/32) LCIS, 6.3% (2/32) LCIS + ALH, and 3.1% (1/32) unspecified atypia. The most common imaging finding was a mass. Most cases, 81.3% (26/32), underwent subsequent surgical excisional biopsy. A single case of ADH involving and adjacent to an FA was upgraded to FA involved by low-grade DCIS on excision for an overall surgical upgrade rate of 3.8%. There were no cases upgraded to invasive malignancy. For those omitting surgical excision, there was no subsequent malignancy diagnosis at the FA biopsy site over a mean follow-up of 73 months.

Conclusion: Cases of radiologic-pathologic concordant FAs involved by atypia have a low upgrade rate of 3.8% and should undergo multidisciplinary review. Larger multi-institutional analysis is needed to determine whether guidelines for excision of atypia should apply to atypia involving FAs.

目的:非典型纤维腺瘤(FA)很少见。由于报告手术升级为乳腺导管原位癌(DCIS)或浸润性恶性肿瘤的数据有限,目前尚不存在通过图像引导活检确诊的非典型纤维腺瘤处理共识指南。因此,这些病变通常需要进行手术切除:这项单一机构的回顾性研究确定了2014年1月至2023年4月期间通过图像引导活检确诊的非典型导管增生(ADH)、非典型小叶增生(ALH)和/或小叶原位癌(LCIS)累及的FA病例,以确定升级率。结果:在通过影像引导活检确诊的1736例FA中,有32例(1.8%)的FA被不典型性所累及,包括43.8%(14/32)ALH、28.1%(9/32)ADH、18.8%(6/32)LCIS、6.3%(2/32)LCIS + ALH和3.1%(1/32)不明不典型性。最常见的影像学发现是肿块。大多数病例(81.3%,26/32)随后接受了手术切除活检。一例ADH累及并邻近FA的病例在切除后升级为低级别DCIS累及FA,手术升级率为3.8%。没有病例升级为浸润性恶性肿瘤。对于那些放弃手术切除的病例,在平均73个月的随访中,FA活检部位没有发现恶性肿瘤:结论:放射学与病理学一致的非典型FA病例升级率较低,仅为3.8%,应接受多学科审查。需要进行更大规模的多机构分析,以确定切除不典型性的指南是否应适用于涉及FA的不典型性。
{"title":"Atypia Involving Fibroadenomas: Outcomes and Upgrade Rates.","authors":"Allison Aripoli, Onalisa Winblad, Christa Balanoff, Jessica Peterson, Camron Smith, Ashley Huppe, Molly Hill, Daniela Wermuth, Nika Gloyeske","doi":"10.1093/jbi/wbae013","DOIUrl":"10.1093/jbi/wbae013","url":null,"abstract":"<p><strong>Objective: </strong>Fibroadenomas (FAs) involved by atypia are rare. Consensus guidelines for management of FAs involved by atypia when diagnosed on image-guided biopsy do not exist because of limited data reporting surgical upgrade rates to ductal carcinoma in situ (DCIS) or invasive malignancy. Therefore, these lesions commonly undergo surgical excision.</p><p><strong>Methods: </strong>This single-institution retrospective study identified cases of FAs involved by atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and/or lobular carcinoma in situ (LCIS) diagnosed on image-guided biopsy between January 2014 and April 2023 to determine upgrade rates. Cases with incidental atypia adjacent to but not involving FAs were excluded.</p><p><strong>Results: </strong>Among 1736 FAs diagnosed on image-guided biopsy, 32 cases (1.8%) were FAs involved by atypia including 43.8% (14/32) ALH, 28.1% (9/32) ADH, 18.8% (6/32) LCIS, 6.3% (2/32) LCIS + ALH, and 3.1% (1/32) unspecified atypia. The most common imaging finding was a mass. Most cases, 81.3% (26/32), underwent subsequent surgical excisional biopsy. A single case of ADH involving and adjacent to an FA was upgraded to FA involved by low-grade DCIS on excision for an overall surgical upgrade rate of 3.8%. There were no cases upgraded to invasive malignancy. For those omitting surgical excision, there was no subsequent malignancy diagnosis at the FA biopsy site over a mean follow-up of 73 months.</p><p><strong>Conclusion: </strong>Cases of radiologic-pathologic concordant FAs involved by atypia have a low upgrade rate of 3.8% and should undergo multidisciplinary review. Larger multi-institutional analysis is needed to determine whether guidelines for excision of atypia should apply to atypia involving FAs.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening the Implant-Augmented Breast with Digital Breast Tomosynthesis: Is Tomosynthesis Necessary for Non-implant-Displaced Views? 用数字乳腺断层合成技术筛查植入假体的乳房:非植入物移位视图是否需要断层合成?
IF 1.5 Q3 Medicine Pub Date : 2024-05-27 DOI: 10.1093/jbi/wbae021
Derek L Nguyen, Lars J Grimm, Jeffrey S Nelson, Karen S Johnson, Sujata V Ghate

Objective: To determine cancer visualization utility and radiation dose for non-implant-displaced (ID) views using standard protocol with digital breast tomosynthesis (DBT) vs alternative protocol with 2D only when screening women with implant augmentation.

Methods: This retrospective cohort study identified women with implants who underwent screening DBT examinations that had abnormal findings from July 28, 2014, to December 31, 2021. Three fellowship-trained breast radiologists independently reviewed examinations retrospectively to determine if the initially identified abnormalities could be visualized on standard protocol (DBT with synthesized 2D (S2D) for ID and non-ID views) and alternate protocol (DBT with S2D for ID and only the S2D images for non-ID views). Estimated exam average glandular dose (AGD) and associations between cancer visualization with patient and implant characteristics for both protocols were evaluated.

Results: The study included 195 patients (mean age 55 years ± 10) with 223 abnormal findings. Subsequent biopsy was performed for 86 abnormalities: 59 (69%) benign, 8 (9%) high risk, and 19 (22%) malignant. There was no significant difference in malignancy visualization rate between standard (19/223, 8.5%) and alternate (18/223, 8.1%) protocols (P = .92), but inclusion of the DBT for non-ID views found one additional malignancy. Total examination AGD using standard protocol (21.9 mGy ± 5.0) was significantly higher than it would be for estimated alternate protocol (12.6 mGy ± 5.0, P <.001). This remained true when stratified by breast thickness: 6.0-7.9 cm, 8.0-9.9 cm, >10.0 cm (all P <.001).

Conclusion: The inclusion of DBT for non-ID views did not significantly increase the cancer visualization rate but did significantly increase overall examination AGD.

目的:确定在对植入假体隆胸的女性进行筛查时,使用数字乳腺断层合成(DBT)的标准方案与仅使用 2D 的替代方案进行非植入物移位(ID)视图的癌症可视化效用和辐射剂量:这项回顾性队列研究确定了从 2014 年 7 月 28 日至 2021 年 12 月 31 日期间接受筛查 DBT 检查并发现异常的植入假体的女性。三位接受过研究员培训的乳腺放射科医生独立回顾性地审查了检查结果,以确定最初发现的异常是否可以通过标准方案(ID 和非 ID 视图采用合成 2D (S2D) DBT)和备用方案(ID 视图采用 S2D DBT,非 ID 视图仅采用 S2D 图像)观察到。对两种方案的估计检查平均腺体剂量(AGD)以及癌症可视化与患者和植入物特征之间的关联进行了评估:研究包括 195 名患者(平均年龄 55 岁 ± 10),共发现 223 个异常结果。随后对 86 例异常进行了活检:59例(69%)良性,8例(9%)高危,19例(22%)恶性。标准方案(19/223,8.5%)和备用方案(18/223,8.1%)在恶性肿瘤显像率方面没有明显差异(P =.92),但在非 ID 视图中加入 DBT 发现了一个额外的恶性肿瘤。使用标准方案进行检查的总 AGD(21.9 mGy ± 5.0)明显高于估计的备用方案(12.6 mGy ± 5.0,P 10.0 cm)(均为 P 结论):将DBT纳入非ID视图并未明显提高癌症显像率,但确实明显增加了整体检查的AGD。
{"title":"Screening the Implant-Augmented Breast with Digital Breast Tomosynthesis: Is Tomosynthesis Necessary for Non-implant-Displaced Views?","authors":"Derek L Nguyen, Lars J Grimm, Jeffrey S Nelson, Karen S Johnson, Sujata V Ghate","doi":"10.1093/jbi/wbae021","DOIUrl":"10.1093/jbi/wbae021","url":null,"abstract":"<p><strong>Objective: </strong>To determine cancer visualization utility and radiation dose for non-implant-displaced (ID) views using standard protocol with digital breast tomosynthesis (DBT) vs alternative protocol with 2D only when screening women with implant augmentation.</p><p><strong>Methods: </strong>This retrospective cohort study identified women with implants who underwent screening DBT examinations that had abnormal findings from July 28, 2014, to December 31, 2021. Three fellowship-trained breast radiologists independently reviewed examinations retrospectively to determine if the initially identified abnormalities could be visualized on standard protocol (DBT with synthesized 2D (S2D) for ID and non-ID views) and alternate protocol (DBT with S2D for ID and only the S2D images for non-ID views). Estimated exam average glandular dose (AGD) and associations between cancer visualization with patient and implant characteristics for both protocols were evaluated.</p><p><strong>Results: </strong>The study included 195 patients (mean age 55 years ± 10) with 223 abnormal findings. Subsequent biopsy was performed for 86 abnormalities: 59 (69%) benign, 8 (9%) high risk, and 19 (22%) malignant. There was no significant difference in malignancy visualization rate between standard (19/223, 8.5%) and alternate (18/223, 8.1%) protocols (P = .92), but inclusion of the DBT for non-ID views found one additional malignancy. Total examination AGD using standard protocol (21.9 mGy ± 5.0) was significantly higher than it would be for estimated alternate protocol (12.6 mGy ± 5.0, P <.001). This remained true when stratified by breast thickness: 6.0-7.9 cm, 8.0-9.9 cm, >10.0 cm (all P <.001).</p><p><strong>Conclusion: </strong>The inclusion of DBT for non-ID views did not significantly increase the cancer visualization rate but did significantly increase overall examination AGD.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11129616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast Implant Imaging: What Is Your Practice? 乳房植入成像:您的实践是什么?
IF 1.5 Q3 Medicine Pub Date : 2024-05-27 DOI: 10.1093/jbi/wbae029
Wendy B DeMartini
{"title":"Breast Implant Imaging: What Is Your Practice?","authors":"Wendy B DeMartini","doi":"10.1093/jbi/wbae029","DOIUrl":"https://doi.org/10.1093/jbi/wbae029","url":null,"abstract":"","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141155338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Appropriate Use of Medical Interpreters in the Breast Imaging Clinic. 在乳腺成像诊所适当使用医疗口译员。
IF 1.5 Q3 Medicine Pub Date : 2024-05-27 DOI: 10.1093/jbi/wbad109
Yara Z Feliciano-Rivera, Monica M Yepes, Priscila Sanchez, Megan Kalambo, Fatima Elahi, Rifat A Wahab, Tatianie Jackson, Tejas Mehta, Jose Net

More than 25 million Americans have limited English-language proficiency (LEP) according to the U.S. Census Bureau. This population experiences challenges accessing health care and is least likely to receive preventive health care, including screening mammogram. In a setting where the breast radiologist does not speak the language of their patient, using certified medical interpreter services is fundamental. Medical interpreter use is associated with improved clinical care and patient satisfaction and can potentially increase adherence to screening mammograms and follow-up in patients with LEP. Title VI of the Civil Rights Act requires interpreter services for patients with LEP who are receiving federal financial assistance. Failure to provide interpretative services when necessary is considered discriminatory and illegal. The use of untrained medical interpreters, including ad hoc interpreters (eg, family, friends, or untrained staff), is associated with more medical errors, violation of confidentiality, and poor health outcomes. Types of medical interpretation services available to address language barriers include in-person interpretation, telephone and video remote interpretation, and qualified bilingual staff. Proper training and certification of medical interpreters is essential to prevent misinterpretations and ensure patient safety. When using an interpreter service, speak to and maintain eye contact with the patient, address the patient directly and seat the interpreter next to or slightly behind the patient, use visual aids whenever possible, and have the patient repeat the information to verify comprehension. Breast radiologists can address disparities in breast cancer screening and treatment by promoting effective communication.

根据美国人口普查局(U.S. Census Bureau)的数据,超过 2500 万美国人英语水平有限(LEP)。这些人在获得医疗保健服务方面面临着挑战,而且最不可能接受预防性医疗保健服务,包括乳房 X 光筛查。在乳腺放射科医生不讲患者语言的情况下,使用经认证的医疗口译服务至关重要。医疗口译员的使用与临床护理的改善和患者满意度的提高有关,并有可能提高 LEP 患者对乳房 X 光筛查和随访的依从性。民权法案》第六章要求为接受联邦财政援助的精通英语的患者提供口译服务。必要时不提供口译服务被视为歧视和违法行为。使用未经培训的医疗口译员,包括临时口译员(如家人、朋友或未经培训的工作人员),会导致更多的医疗差错、违反保密规定和不良的医疗效果。可用于解决语言障碍的医疗口译服务类型包括面对面口译、电话和视频远程口译以及合格的双语工作人员。对医疗口译员进行适当的培训和认证对于防止误译和确保患者安全至关重要。使用口译服务时,应与患者交谈并保持目光接触,直接称呼患者,让口译员坐在患者旁边或稍后的位置,尽可能使用视觉辅助工具,并让患者重复信息以确认是否理解。乳腺放射科医生可以通过促进有效沟通来解决乳腺癌筛查和治疗中的不平等问题。
{"title":"Appropriate Use of Medical Interpreters in the Breast Imaging Clinic.","authors":"Yara Z Feliciano-Rivera, Monica M Yepes, Priscila Sanchez, Megan Kalambo, Fatima Elahi, Rifat A Wahab, Tatianie Jackson, Tejas Mehta, Jose Net","doi":"10.1093/jbi/wbad109","DOIUrl":"10.1093/jbi/wbad109","url":null,"abstract":"<p><p>More than 25 million Americans have limited English-language proficiency (LEP) according to the U.S. Census Bureau. This population experiences challenges accessing health care and is least likely to receive preventive health care, including screening mammogram. In a setting where the breast radiologist does not speak the language of their patient, using certified medical interpreter services is fundamental. Medical interpreter use is associated with improved clinical care and patient satisfaction and can potentially increase adherence to screening mammograms and follow-up in patients with LEP. Title VI of the Civil Rights Act requires interpreter services for patients with LEP who are receiving federal financial assistance. Failure to provide interpretative services when necessary is considered discriminatory and illegal. The use of untrained medical interpreters, including ad hoc interpreters (eg, family, friends, or untrained staff), is associated with more medical errors, violation of confidentiality, and poor health outcomes. Types of medical interpretation services available to address language barriers include in-person interpretation, telephone and video remote interpretation, and qualified bilingual staff. Proper training and certification of medical interpreters is essential to prevent misinterpretations and ensure patient safety. When using an interpreter service, speak to and maintain eye contact with the patient, address the patient directly and seat the interpreter next to or slightly behind the patient, use visual aids whenever possible, and have the patient repeat the information to verify comprehension. Breast radiologists can address disparities in breast cancer screening and treatment by promoting effective communication.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139547361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Breast Imaging
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1